Loading...
Benefit-Risk Analysis of Buprenorphine for Pain Management
Hale, Martin Garofoli, Mark Raffa, Robert B.
Hale, Martin
Garofoli, Mark
Raffa, Robert B.
Citations
Altmetric:
Genre
Journal article
Date
2021-05-24
Advisor
Committee member
Group
Department
Pharmeceutical Sciences
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.2147/jpr.s305146
Abstract
Health care providers in the United States are facing challenges in selecting appropriate medication for patients with acute and chronic pain in the midst of the current opioid crisis and COVID-19 pandemic. When compared with conventional opioids, the partial μ-opioid receptor agonist buprenorphine has unique pharmacologic properties that may be more desirable for pain management. The formulations of buprenorphine approved by the US Food and Drug Administration for pain management include intravenous injection, transdermal patch, and buccal film. A comparison of efficacy and safety data from studies of buprenorphine and conventional opioids suggests that buprenorphine may be a better-tolerated treatment option for many patients that provides similar or superior analgesia. Our benefit-risk assessment in this narrative review suggests that health care providers should consider that buprenorphine may be an appropriate alternative for pain management over other opioids.
Description
Citation
Hale M, Garofoli M, Raffa RB. Benefit-Risk Analysis of Buprenorphine for Pain Management. J Pain Res. 2021;14:1359-1369, https://doi.org/10.2147/JPR.S305146
Citation to related work
Dove Medical Press
Has part
Journal of Pain Research, Vol. 14
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu